Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HanchorBioTPE:7827 -0.32%9 Market Cap is NT$21,778.4 Mil as of Aug. 10, 2026. GuruFocus rates TPE:7827 with a GF Score™ of 9/100. Among 1,419 Biotechnology companies, HanchorBio ranks better than 74.56% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). HanchorBio's share price for the quarter that ended in Mar. 2026 was NT$123.5. HanchorBio's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 130.3 Mil. Therefore, HanchorBio's market cap for the quarter that ended in Mar. 2026 was NT$16,093.3 Mil.
HanchorBio's quarterly market cap
increased
from Sep. 2025 (NT$10,083.4 Mil) to Dec. 2025 (NT$11,493.0 Mil) and
increased
from Dec. 2025 (NT$11,493.0 Mil) to Mar. 2026 (NT$16,093.3 Mil).
HanchorBio's annual market cap
stayed the same
from Dec. 2023 (NT$0.0 Mil) to Dec. 2024 (NT$0.0 Mil) but then
increased
from Dec. 2024 (NT$0.0 Mil) to Dec. 2025 (NT$11,493.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. HanchorBio's Enterprise Value for Today is NT$21,167.7 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
HanchorBio Market Cap Related Terms
HanchorBio Market Cap Historical Data
* Premium members only.
The historical data trend for HanchorBio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:7827 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, HanchorBio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HanchorBio Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HanchorBio's Market Cap distribution charts can be found below:
* The bar in red indicates where HanchorBio's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
HanchorBio's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HanchorBio (TPE:7827) has a Market Cap of NT$21,778.4 Mil as of Aug. 10, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on HanchorBio and its competitors. According to the industry distribution chart, HanchorBio ranks #361 out of 1419 companies in the Biotechnology industry, placing it in the top 25.4%.
Is HanchorBio's Market Cap too high?
HanchorBio's current Market Cap is NT$21,778.4 Mil. Based on the distribution chart, HanchorBio ranks #361 out of 1419 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HanchorBio has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does HanchorBio's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HanchorBio ranks #361 out of 1419 companies for Market Cap. This puts HanchorBio in the upper half of its industry. The industry median Market Cap is 116.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 116.54, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on HanchorBio and its competitors. For the Biotechnology industry, the median Market Cap is 116.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HanchorBio's current Market Cap is NT$21,778.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HanchorBio stock overvalued right now?
HanchorBio (TPE:7827) has a current Market Cap of NT$21,778.4 Mil. The current Market Cap is NT$21,778.4 Mil. HanchorBio's overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For HanchorBio (TPE:7827), the current Market Cap is NT$21,778.4 Mil as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HanchorBio Inc through its subsidiaries, is conducting research and development of new anti-cancer drugs, utilizing an Fc-based biopharmaceutical platform technology to reactivate the immune system in the fight against disease. The core technology of HanchorBio is the FBDB (Fc-Based Designer Biologics) platform, which focuses on the development of next-generation immuno-oncology fusion protein therapeutics. This platform utilizes the antibody Fc region as a backbone, onto which various engineered anti-cancer molecules are constructed through protein engineering. Combined with AI-assisted drug design capabilities, this technology is dedicated to overcoming key challenges in tumor immunotherapy.
9GF Score
Get the complete analysis for TPE:7827
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:7827 has been successfully added to your 
